Volume 21, Number 6—June 2015
Research
Oral Cholera Vaccine Coverage, Barriers to Vaccination, and Adverse Events following Vaccination, Haiti, 20131
, Jeannot François, Kathleen Wannemuehler, Preetha Iyengar, Amber Dismer, Paul Adrien, Terri B. Hyde, Barbara J. Marston, Kashmira A. Date, Eric D. Mintz, and Mark A. Katz
Table 2
Estimated oral cholera vaccination coverage, Haiti, 2013*
| No. doses Received | Area, % (95% CI) |
||||||
|---|---|---|---|---|---|---|---|
| Petite Anse |
Cerca Carvajal |
||||||
| Total, n = 1,118 | Male, n = 497 | Female, n = 621 | Total, n = 808 | Male, n = 407 | Female, n = 401 | ||
| Total | |||||||
| 2 | 62.5 (57.9–66.9) | 59.8 (53.9–65.5) | 64.5 (58.8–69.7) | 76.8 (71.1–81.8) | 69.0 (60.4–76.4) | 84.9 (80.0–88.8) | |
| 1 | 6.6 (4.9–8.9) | 7.1 (4.7–10.4) | 6.3 (3.8–10.2) | 7.0 (4.7–10.5) | 10.0 (6.3–15.4) | 4.0 (2.4–6.8) | |
| 0 | 30.9 (26.8–35.3) | 33.1 (27.6–39.1) | 29.2 (24.8–34.1) | 16.1 (12.4–20.6) | 21.1 (15.3–28.3) | 11.0 (7.9–15.2) | |
| Age group, y | |||||||
| 1–4 | n = 206 | n = 102 | n = 104 | n = 191 | n = 91 | n = 100 | |
| 2 | 67.9 (60.2–74.8)† | 63.9 (52.8–73.6) | 71.8 (62.5–79.5) | 81.6 (72.9–88.0)† | 87.5 (75.5–94.1) | 76.1 (63.1–85.6) | |
| 1 | 2.4 (0.8–6.9) | 4.5 (1.4–13.4) | 0.3 (0.0–2.4) | 5.8 (2.7–12.0) | 3.5 (0.8–13.9) | 7.9 (3.2–18.5) | |
| 0 | 29.7 (23.3–37.0) | 31.6 (22.3–42.5) | 27.9 (20.3–37.1) | 12.6 (7.9–19.6) | 9.1 (4.1–18.8) | 16.0 (9.1–26.5) | |
| 5–14 | n = 351 | n = 163 | n = 188 | n = 263 | n = 148 | n = 115 | |
| 2 | 77.9 (71.7–83.0)† | 75.5 (65.1–83.6) | 79.8 (72.4–85.6) | 83.8 (75.0–89.9)† | 76.5 (63.6–85.9) | 92.9 (85.1–96.7) | |
| 1 | 5.8 (3.7–9.0) | 6.1 (3.1–11.3) | 5.6 (3.0–10.3) | 5.5 (2.8–10.8) | 8.5 (4.0–17.2) | 1.8 (0.6–5.5) | |
| 0 | 16.3 (12.1–21.7) | 18.4 (11.5–28.2) | 14.6 (9.8–21.2) | 10.7 (6.2–17.7) | 15.0 (8.3–25.5) | 5.4 (2.0–13.7) | |
| >15 y | n = 561 | n = 232 | n = 329 | n = 354 | n = 168 | n = 186 | |
| 2 | 55.7 (50.0–61.3)† | 52.5 (44.8–60.0) | 58.0 (50.7–65.0) | 70.8 (63.9–76.9)† | 57.9 (47.4–67.8) | 82.7 (75.7–88.0) | |
| 1 | 7.6 (5.3–10.9) | 7.9 (4.5–13.6) | 7.4 (4.0–13.2) | 8.4 (5.3–13.1) | 12.9 (7.6–21.1) | 4.3 (2.1–8.6) | |
| 0 | 36.7 (31.5–42.1) | 39.6 (32.4–47.2) | 34.6 (28.7–41.0) | 20.8 (15.7–27.0) | 29.2 (20.5–39.7) | 13.0 (8.6–19.2) | |
*Vaccination status was assessed from special cards distributed to document doses administered during the campaign, if available, or by recall; in every selected household, 1 person was randomly selected from each age group. Statistical analyses accounted for the weights and the study design.
†Design effect (DE) and estimated intraclass correlations (ICC) = (DE−1)/(b−1), where b is the average number of responses per cluster. DE is based on accounting for clustering only (The finite population correction and weighting are ignored). Petite Anse: age group: 1–4 y, DE = 1.3 and ICC = 0.05; 5–14 y, DE = 1.4 and ICC = 0.04; >15 y, DE = 2.1 and ICC = 0.06. Cerca Carvajal: age group 1–4 y, DE = 2.4 and ICC = 0.15; 5–14 y, DE = 3.9 and ICC = 0.22; >15 y; DE = 2.3 and ICC = 0.07.
1Results from this study were partially presented at the 49th US–Japan Conference on Cholera and Other Enteric Bacterial Infections; 2015 Jan 14–16; Gainesville, Florida, USA.